Ana M Rodriguez1, Efstathia Polychronopoulou2, Enshuo Hsu2, Rahul Shah3, Kelly Lamiman4, Yong-Fang Kuo2. 1. Department of Obstetrics & Gynecology, USA; Sealy Institute for Vaccine Sciences, USA. Electronic address: an3rodri@utmb.edu. 2. Department of Preventive Medicine and Population Health, USA. 3. School of Medicine, The University of Texas Medical Branch at Galveston, TX, USA. 4. Department of Obstetrics & Gynecology, USA.
Abstract
OBJECTIVE: While disparities in endometrial hyperplasia and endometrial cancer are well documented in Blacks and Whites, limited information exists for Hispanics. The objective is to describe the patient characteristics associated with endometrial hyperplasia symptoms, endometrial hyperplasia with atypia and endometrial cancer, and assess factors contributing to racial/ethnic differences in disease outcomes. METHODS: This single-center, retrospective study included women aged ≥50 years with ≥ two encounters for endometrial hyperplasia symptoms, endometrial hyperplasia with atypia and endometrial cancer between 2012 and 2016. Multivariate logistic regression models evaluated the predictors of endometrial cancer and hyperplasia. RESULTS: We included 19,865 women (4749 endometrial hyperplasia symptoms, 71 endometrial hyperplasias with atypia, 201 endometrial cancers) with mean age of 60.45 years (SD 9.94). The odds of endometrial hyperplasia symptoms were higher in non-Hispanic Blacks (Odds Ratio [OR] 1.56, 95% Confidence Interval [CI] 1.20-1.72), Hispanics (OR 1.35, 95% CI 1.22-1.49), family history of female cancer (OR 1.25, 95% CI 1.12-1.39), hypertension (OR 1.24, 95% CI 1.14-1.35), and birth control use (OR 1.29, 95% CI 1.15-1.43). Odds of endometrial cancer and atypical hyperplasia increased for ages 60-64 (OR 7.95, 95% CI 3.26-19.37; OR 3.66, 95% 1.01-13.22) and being obese (OR 1.61, 95% CI 1.08-2.41; OR: 6.60, 95% CI 2.32-18.83). Odds of endometrial cancer increased with diabetes (OR 1.68, 95% CI 1.22-2.32). CONCLUSION(S): Patients with obesity and diabetes had increased odds of endometrial cancer and hyperplasia with atypia. Further study is needed to understand the exogenous estrogen effect contributing to the increased incidence among Hispanics.
OBJECTIVE: While disparities in endometrial hyperplasia and endometrial cancer are well documented in Blacks and Whites, limited information exists for Hispanics. The objective is to describe the patient characteristics associated with endometrial hyperplasia symptoms, endometrial hyperplasia with atypia and endometrial cancer, and assess factors contributing to racial/ethnic differences in disease outcomes. METHODS: This single-center, retrospective study included women aged ≥50 years with ≥ two encounters for endometrial hyperplasia symptoms, endometrial hyperplasia with atypia and endometrial cancer between 2012 and 2016. Multivariate logistic regression models evaluated the predictors of endometrial cancer and hyperplasia. RESULTS: We included 19,865 women (4749 endometrial hyperplasia symptoms, 71 endometrial hyperplasias with atypia, 201 endometrial cancers) with mean age of 60.45 years (SD 9.94). The odds of endometrial hyperplasia symptoms were higher in non-Hispanic Blacks (Odds Ratio [OR] 1.56, 95% Confidence Interval [CI] 1.20-1.72), Hispanics (OR 1.35, 95% CI 1.22-1.49), family history of female cancer (OR 1.25, 95% CI 1.12-1.39), hypertension (OR 1.24, 95% CI 1.14-1.35), and birth control use (OR 1.29, 95% CI 1.15-1.43). Odds of endometrial cancer and atypical hyperplasia increased for ages 60-64 (OR 7.95, 95% CI 3.26-19.37; OR 3.66, 95% 1.01-13.22) and being obese (OR 1.61, 95% CI 1.08-2.41; OR: 6.60, 95% CI 2.32-18.83). Odds of endometrial cancer increased with diabetes (OR 1.68, 95% CI 1.22-2.32). CONCLUSION(S): Patients with obesity and diabetes had increased odds of endometrial cancer and hyperplasia with atypia. Further study is needed to understand the exogenous estrogen effect contributing to the increased incidence among Hispanics.
Authors: Meira Epplein; Susan D Reed; Lynda F Voigt; Katherine M Newton; Victoria L Holt; Noel S Weiss Journal: Am J Epidemiol Date: 2008-08-05 Impact factor: 4.897
Authors: Amy J Bregar; J Alejandro Rauh-Hain; Ryan Spencer; Joel T Clemmer; John O Schorge; Laurel W Rice; Marcela G Del Carmen Journal: Gynecol Oncol Date: 2017-02-01 Impact factor: 5.482
Authors: Antonio Travaglino; Antonio Raffone; Gabriele Saccone; Antonio Mollo; Giuseppe De Placido; Massimo Mascolo; Luigi Insabato; Fulvio Zullo Journal: APMIS Date: 2019-03-19 Impact factor: 3.205
Authors: Sara H Olson; Coral L Atoria; Michele L Cote; Linda S Cook; Radhai Rastogi; Robert A Soslow; Carol L Brown; Elena B Elkin Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-03-16 Impact factor: 4.254
Authors: Linda S Cook; Harold E Nelson; Myles Cockburn; Sara H Olson; Carolyn Y Muller; Charles L Wiggins Journal: Cancer Causes Control Date: 2012-10-30 Impact factor: 2.506
Authors: Oluwole A Babatunde; Swann Arp Adams; Jan M Eberth; Michael D Wirth; Seul Ki Choi; James R Hebert Journal: Cancer Causes Control Date: 2016-02-01 Impact factor: 2.506
Authors: Jae H Kang; Angela S Kueck; Richard Stevens; Gary Curhan; Immaculata De Vivo; Bernard Rosner; Erik Alexander; Shelley S Tworoger Journal: Obstet Gynecol Int Date: 2013-07-15